Loading patent…
AssigneeSynaptic Pharmaceutical Corporation
InventorsKelli E. Smith, Laurence A. Borden, Richard L. Weinshank, Paul R. Hartig
Estimating the term…
This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding normal or mutant mammalian GABA or taurine transporters, or normal or mutant human GABA or taurine transporters are provided. Further provided are methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian GABA or taurine transporters, or human GABA or taurine transporters.
An isolated nucleic acid molecule encoding a mammalian GABA transporter.
An isolated nucleic acid molecule encoding a mammalian taurine transporter.
A method for isolating a nucleic acid molecule encoding a human taurine transporter by nucleic acid sequence homology using natural sequences or artificial sequences, the sequences of which are derived from sequences in FIGS. 1A-1D, 2A-2D, 3A-3D, 14A-14B or 15A-15D.
An isolated mammalian GABA transporter protein.
An isolated mammalian taurine transporter protein.
A plasmid designated pEVJB-rB14b (ATCC Accession No. 75203).
A plasmid designated pEVJB-rB8b (ATCC Accession No. 75201).
A plasmid designated pEVJB-rB16a (ATCC Accession No. 75202).
A plasmid designated pcEXV-hGAT-3 (ATCC Accession No. 75324).
A plasmid designated pBluescript-hHe7a (ATCC Accession No. 75322).
A plasmid designated pBluescript-hS3a (ATCC Accession No. 75323).
A mammalian cell comprising a plasmid which further comprises a vector which encodes a mammalian GABA transporter.
A nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a mammalian GABA transporter.
A nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a mammalian taurine transporter.
An antisense oligonucleotide having a sequence capable of binding specifically to an mRNA molecule encoding a mammalian GABA transporter so as to prevent translation of the mRNA molecule.
An antisense oligonucleotide having a sequence capable of binding specifically to an mRNA molecule encoding a mammalian taurine transporter so as to prevent translation of the mRNA molecule.
A monoclonal antibody directed to a mammalian GABA transporter.
A monoclonal antibody directed to a mammalian taurine transporter.
A pharmaceutical composition comprising an amount of a substance effective to alleviate the abnormalities resulting from overexpression of a mammalian GABA transporter and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an amount of a substance effective to alleviate the abnormalities resulting from overexpression of a mammalian taurine transporter and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an amount of a substance effective to alleviate abnormalities resulting from underexpression of GABA transporter and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an amount of a substance effective to alleviate abnormalities resulting from underexpression of taurine transporter and a pharmaceutically acceptable carrier.
A transgenic nonhuman mammal whose genome comprises DNA encoding a mammalian GABA transporter so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding a GABA transporter and which hybridizes to mRNA encoding a GABA transporter thereby reducing its translation.
A transgenic nonhuman mammal whose genome comprises DNA encoding a mammalian taurine transporter so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding a taurine transporter and which hybridizes to mRNA encoding a taurine transporter thereby reducing its translation.
A transgenic nonhuman mammal whose genome comprises DNA complementary to DNA encoding a mammalian GABA transporter so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding the transporter and which hybridizes to mRNA encoding the transporter thereby preventing its translation.
A transgenic nonhuman mammal whose genome comprises DNA complementary to DNA encoding a mammalian taurine transporter so placed as to be transcribed into antisense mRNA which is complementary to mRNA encoding the transporter and which hybridizes to mRNA encoding the transporter thereby preventing its translation.
A method of determining the physiological effects of expressing varying levels of mammalian GABA transporters which comprises producing a transgenic nonhuman animal whose levels of mammalian GABA transporter expression are varied by use of an inducible promoter which regulates mammalian GABA transporter expression.
A method of determining the physiological effects of expressing varying levels of mammalian taurine transporters which comprises producing a transgenic nonhuman animal whose levels of mammalian taurine transporter expression are varied by use of an inducible promoter which regulates mammalian taurine transporter expression.
A method of determining the physiological effects of expressing varying levels of mammalian GABA transporters which comprises producing a panel of transgenic nonhuman animals each expressing a different amount of mammalian GABA transporter.
A method of determining the physiological effects of expressing varying levels of mammalian taurine transporters which comprises producing a panel of transgenic nonhuman animals each expressing a different amount of mammalian taurine transporter.
A method for diagnosing a predisposition to a disorder associated with the expression of a specific mammalian transporter allele which comprises:
A method for preparing membranes comprising a GABA transporter which comprises:
A method for preparing membranes comprising a taurine transporter which comprises:
A method for isolating vesicles comprising the GABA transporter which comprises:
A method for isolating vesicles comprising a taurine transporter which comprises:
A method of determining whether a ligand not known to be capable of specifically binding to only one human GABA transporter subtype can specifically bind to only one human GABA transporter subtype which comprises:
A method of determining whether a ligand not known to be capable of specifically binding to only one human GABA transporter subtype can specifically bind to only one human GABA transporter subtype which comprises:
A method of determining whether a ligand not known to be capable of specifically inhibiting only one human GABA transporter subtype can specifically inhibit only one human GABA transporter subtype which comprises:
A method of determining whether a ligand not known to specifically inhibit only the human GAT-1 transporter subtype can specifically inhibit only the human GAT-1 transporter subtype which comprises:
Dependencies are inferred from the claim text.